IRX-2 MECHANISMS OF ACTION

THE NEED FOR MULTIPLE MECHANISMS OF ACTION IN CANCER IMMUNOTHERAPY

Given the numerous cellular defects present in cancer, IRX believes that any single receptor cannot restore all cellular immune responses. Therefore:

  • Multiple mechanisms must be enlisted for an effective cellular immune response
  • There may be a benefit to a biologic with multiple active components versus a single cytokine
  • There may be synergy among these components, because the language of the immune system consists of multiple cytokines

IRX-2 MECHANISMS OF ACTION

The active components in IRX-2 induce dendritic cell (DC) activation and maturation, as well as T-cell activation and protection from apoptosis, initiating an effective cellular antitumor immune response.

  • The induction of the antitumor response is mediated by antigen-presenting DCs that present tumor-specific antigens and drive the subsequent expansion of antigen-specific T cells1,2
  • T-cells are protected from tumor-induced apoptosis3,4
  • These tumor-specific cytotoxic killer T cells then infiltrate and kill the tumor5-7

IRX-2 MECHANISMS OF ACTION

MOA

APC, antigen-presenting cell; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN, interferon; IL, interleukin.

IRX-2 MECHANISM OF ACTION IN HEAD AND NECK SQUAMOUS CELL CARCINOMA

In head and neck squamous cell carcinoma (HNSCC), IRX-2 is thought to

  • Act on immune cells in peripheral circulation, fostering activation and maturation of DCs and T cells and enhancing the presentation of endogenous HNSCC antigen to naïve T cells8
  • Enhance infiltration of leukocytes into HNSCC tumors9,10

© 2016 IRX Therapeutics